Delta-Fly Pharma 4598.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4598.T. It has been listed since 12 October 2018. In the fiscal year to 31 March 2022, it reported revenue of ¥300.0m and a net loss of ¥967.3m. At that date it held total assets of ¥1.32bn and shareholders' equity of ¥1.23bn.

Delta-Fly Pharma, Inc. engages in the manufacturing, sale, research and development of pharmaceutical products for cancer treatment. The company is headquartered in Tokushima-Shi, Tokushima-Ken. The company went IPO on 2018-10-12. The firm's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Kiyoshi EshimaPresident, Chief Executive Officer, Representative Director, since 2010
• Mr. Kenichi KurotakiDirector
• Mr. Kenzo IizukaDirector, since 2017
• Mr. Sachio KishiiIndependent Director
• Mr. Kinichiro KominamiIndependent Director
• Mr. Akifumi TaniguchiIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.